Scott L Pomeroy M.D., Ph.D

Bronson Crothers Professor of Neurology/Neurologist-in-Chief

Scott L Pomeroy Children's Hospital Intellectual and Developmental Disabilities Research Center
Harvard Medical School
300 Longwood Ave.
Fegan-11
Boston, MA 02115
617-355-6874 (tel)
617-730-0286 (fax)
Scott.Pomeroy@childrens.harvard.edu
http://www.iddrc.org/childrens-hospital-boston/index.php

Biography/Curriculum Vitae:

Research Interests:
Clinical/Translational Neuroscience, Neuro-oncology

Narrative of Current Research Efforts:

Brain tumors are the most common cause of cancer death in children, and a major cause of neurological disability for those who survive them. Since 1992, the Pomeroy lab has developed a program focused on translational and basic research into the molecular basis of embryonal tumors that arise in the developing nervous system. The group has become a central component of the research effort for Pediatric Neuro-oncology in the Dana Farber/Harvard Cancer Center, and a significant contributor to national research programs in the Children’s Oncology Group and Pediatric Brain Tumor Consortium. Their research has been incorporated into all national phase III protocols for embryonal tumors in the . Moreover, the group has created genomic databases of embryonal tumors that are freely accessible on the internet to investigators throughout the world from Websites at the MIT/Harvard Broad Institute and the National Cancer Institute.

The goal of this group is to change the way that embryonal tumors are treated, moving from traditional radiation and chemotherapy to biological approaches based on targeted molecular therapies. To this end, the lab has focused on understanding the molecular basis of embryonal tumor oncogenesis within the context of the developing central nervous system. To provide a practical means to implement this change, they have created research infrastructure within national cooperative therapy groups to provide access to research materials for investigators throughout the world and to develop protocols that will enable the rapid incorporation of new therapies into clinical trials.

 



Major Honors and Awards:


Representative Publications:

Aguir, R., Cox, G., Pomeroy, S. L. and Dahia, P., 2001. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas. J Clin Endocrinol Metab. 86, 2890-2894.

Carpentieri, S. C., Waber, D. P., Scott, R. M., Goumnerova, L. C., Kieran, M. w., Cohen, L., Kim, F., Billett, A. L., Tarbell, N. J. and Pomeroy, S. L., 2001. Memory deficits in children with craniopharyngioma. Neurosurgery. 49, 1053-1058.

Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturia, L. M., Angelo, M., McLaughlin, M., Kim, J. Y., Goumnerova, L. C., Black, P. M., Lau, C., Wetmore, C., Biegel, J., Poggio, T., Mukherjee, S., Rifkin, R., Califano, A., Stolovitzky, G., Louis, D. N., Mesirov, J. P., Lander, E. S. and Golub, T. R., 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 415, 436-442.

Bhattacharya, S., Watson, F., Pomeroy, S., Zhang, Y., Stiles, C. and Segal, R., 2002. High resolution imaging demonstrates dynein based vesicular transport of activated Trk receptors. J Neurobiol. 51, 302-312.

Kim, J. Y., Koralnik, I. J., LeFave, M., Segal, R. A., Pfister, L. A. and Pomeroy, S. L., 2002. Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro-oncol. 4, 165-170..

Louis, D., Pomeroy, S. and Cairncross, J., 2002. Focus on central nervous system neoplasia. Cancer Cell. 1, 125-128.

Strother, D. R., Pollack, I. F., Fisher, P. G., Hunter, J. V., Woo, S. Y., Pomeroy, S. L. and Rorke, L. B., 2002. Tumors of the central nervous system. In: Pizzo, P. A. and Poplak, D. G. (Eds.), Principles and Practice of Pediatric Oncology. Lippincott, Williams and Wilkins, Philadelphia, pp. 751-824.

Nutt, C. L., Mani, D. R., Betensky, R. A., Tamayo, P., Cairncross, J. G., Ladd, C., Pohl, U., Hartmann, C., Mc Laughlin, M. E., Batchelor, T. T., Black, P. M., von Deimling, A., Pomeroy, S. L., Golub, T. R. and Louis, D. N., 2003. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602-1607.

Nelson, A. L., Algon, S. A., Munasinghe, J., Graves, O., Goumnerova, L., Burstein, C., Pomeroy, S. L. and Kim, J. Y. H., 2003. Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J NeuroOncol. 62, 259-267.

McLaughlin, M., Robson, C., Kieran, M., Jacks, T., Pomeroy, S. L. and Cameron, S., 2003. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hem Oncol. 25, 644-648.

Kim, J. Y., Nelson, A. L., Algon, S. A., Graves, O., Sturla, L. M., Goumnerova, L., Rowitch, D. H., Segal, R. A. and Pomeroy, S. L., 2003. Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol. 263, 50-66.

Sturla, L.-M., Fernandez-Teijeiro, A. and Pomeroy, S. L., 2003. Application of microarrays to neurological disease. Arch Neurol. 60, 676-682.

Pomeroy, S. L. and Sturla, L.-M., 2003. Molecular biology of medulloblastoma therapy. Pediatr Neurosurg. 39, 299-304.

Ullrich, N. and Pomeroy, S. L., 2003. Pediatric brain tumors. Neurol Clin. 21, 1-17.

Fernandez- Teijeiro, A., Betensky, R. A., Sturla, L. M., Kim, J. H., Tamayo, P. and Pomeroy, S. L., 2004. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 22, 994-998.

Kho, A. T., Zhao, Q., Cai, Z., Butte, A. J., Kim, J. Y., Pomeroy, S. L., Rowitch, D. H. and Kohane, I. S., 2004. Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 18, 629-640.

Pomeroy, S. L., 2004. Neural development and the ontogeny of central nervous system tumors. Neuron Glia Biol. 1, 127-133.

Ullrich, N. and Pomeroy, S. L., 2003. Development of the nervous system. In: Polin, R. and Fox, W. (Eds.), Neonatal and Fetal Medicine. WB Saunders, Philadelphia, pp. 1675-1698.

Ullrich, N., Scott, R. M. and Pomeroy, S. L., 2005. Craniopharyngioma tratment: long term effects on hypothalamic function. Neurologist. 11, 55-60.

Alexander, R., Judkins, A. R., Burger, P. C., Hamilton, R. L., Kleinschmidt- DeMasters, B., Perry, A., Pomeroy, S. L., Rosenblu, M., Yachnis, A. T., Zhou, H., Rorke, L. B. and Biegel, J., INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropath Exp Neurol.

Greene, S. and Pomeroy, S. L., 2003. Predicting medulloblastoma outcome. In: Black, P. M. and Loeffler, J. (Eds.), Cancer of the Nervous System. Blackwell, Cambridge, MA, pp. in press.

Ullrich, N. and Pomeroy, S. L., Microarray analysis and proteomic approaches to drug development. In: Newton, H. (Ed.), Handbook of Brain Tmor Chemotherapy. Elsevier.




Created 1/18/2006 by Evette Mezger
Last modified 1/27/2010 by Oksana Klimova